NHS Will Give Wegovy to Over a Million People for Heart Health
The UK just approved Wegovy for 1.2 million people to prevent heart attacks and strokes. Plus, new research shows GLP-1s might help with mental health too.
NHS Makes Wegovy Available for Heart Protection
Starting this summer, the NHS in England will offer Wegovy to 1.2 million overweight people with cardiovascular disease. This isn't about weight loss anymore – it's specifically to prevent heart attacks and strokes.
NICE (the UK's health technology assessment body) approved this expanded use today after reviewing clinical trial data showing /wegovy can reduce major heart events by about 20%. That's pretty significant when you're talking about preventing life-threatening complications.
Here's what's different: you don't need to have diabetes or be seeking weight loss treatment to qualify. If you're overweight and have cardiovascular disease, you could be eligible. The NHS says they've worked out a cost-effective deal with Novo Nordisk to make this happen.
Weight Watchers Cuts Wegovy Costs for Members
Meanwhile in the US, Weight Watchers is making Wegovy more affordable for their Med+ members. They've announced a new agreement that could save eligible members up to $1,200 annually on the medication.
This kind of pricing partnership is becoming more common as companies try to make GLP-1 medications accessible to more people. Still, even with the discount, you're looking at significant out-of-pocket costs if your insurance doesn't cover it.
GLP-1s Might Help With Depression and Anxiety
Here's something that caught our attention: new research from Griffith University suggests GLP-1 medications like semaglutide could help with mental health too. The study, published in The Lancet Psychiatry, found that people taking these drugs had:
- 44% reduction in worsening depression
- 38% reduction in worsening anxiety
- Lower risk of other mental health complications
Before you get too excited, this was specifically in people who already had mental health conditions. We're not talking about using /semaglutide as a first-line depression treatment. But it does suggest these medications might have broader benefits than we initially understood.
Bottom Line
The UK's decision to use Wegovy for heart protection marks a shift from thinking about GLP-1s as just weight loss drugs. Combined with the mental health research, we're seeing these medications potentially help with multiple health issues. If you're in the US, affordability remains the biggest hurdle – though programs like the Weight Watchers discount are starting to help.
